Objective: To determine cord blood angiotensin II (Ang II) concentration and assess its relationship to fetal insulin sensitivity in the offspring of mothers with gestational diabetes mellitus (GDM) at birth.
Introduction
Gestational diabetes mellitus (GDM) has been defined as any degree of glucose intolerance with onset or first recognition during pregnancy. 1 Human long-term follow-up studies indicate that the offspring of mothers with GDM are at significant risk of developing metabolic syndrome (MetS) in their childhood 2 and adulthood. 3 MetS, including overweight, abdominal obesity, hypertension, dyslipidemia and glucose intolerance, strongly correlates with cardiovascular disease. The epidemic of diabetes, GDM and childhood obesity/MetS in Chinese populations has risen rapidly over recent decades. The complex interplay between environmental, genetic and perinatal factors sets up a vicious cycle of 'diabetes begetting diabetes', which results in a high risk of diabetes and MetS in mothers with a history of GDM and their offspring. 4 The concept of developmental origins of health and disease has been defined as the process through which the environment encountered before birth, or in infancy, shapes the long-term control of tissue physiology and homeostasis. 5 Thus, investigation of the metabolic status in the offspring of mothers with GDM at birth may set the basis for further understanding of their related metabolic disorders later in life.
It is widely accepted that decreased insulin sensitivity is an important factor for the pathogenesis of GDM and MetS. Luo et al 6 reported that the effects of maternal glucose tolerance on fetal insulin sensitivity are much stronger than those of maternal adiposity and independent of a genetic influence and other potential confounders. Hence, to determine the effect of maternal glucose tolerance on fetal insulin sensitivity and its possible mechanisms is valuable for the understanding of fetal metabolic disorders. The renin-angiotensin system (RAS) is well known for its critical role in the regulation of cardiovascular system. In addition to this effect, studies showed that the overactive RAS is also involved in the pathogenesis of type 2 diabetes mellitus (T2DM) 7 and MetS. 8 Angiotensin II (Ang II), the active end-product of the RAS, is formed from angiotensin I (Ang I) by the catalyzing of ACE (angiotensin converting enzyme). Ang II, acting via angiotensin type 1 (AT1) receptor, have important roles in insulin sensitivity, vasoconstriction, pro-inflammatory, pro-oxidant and endothelial dysfunction. 9, 10 Moreover, administration of RAS blockades, either ACEIs (ACE inhibitors) or ARBs (angiotensin receptor blockers), can improve insulin sensitivity. 9, 11 Ang II is involved in obesity. In obese patients with T2DM, blood Ang II concentration is associated with body fat accumulation and markers of decreased insulin sensitivity. 12 In diabetic mice, blood Ang II concentration increases, which is normalized by the administration of losartan, one of ARBs. 10 In the untreated streptozotocin-diabetic rats, blood Ang II concentration increases during pregnancy and postpartum. 13 However, the relationship between cord blood Ang II concentration and fetal insulin sensitivity in the offspring of mothers with GDM remains unknown. We aimed to (1) determine whether the offspring of mothers with GDM have increased cord blood Ang II concentration and decreased insulin sensitivity at birth, and (2) assess their relationships.
Methods
The study was approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University in China. All participants gave informed written consent.
Subjects
Pregnant women were screened by undergoing a 75-g oral glucose tolerance test at 20 to 30 weeks of gestation. GDM was diagnosed according to the criteria of the Chinese Diabetes in Pregnancy Society.
14 GDM was defined as having two or more abnormal glucose values at 75-g oral glucose tolerance test (abnormal glucose values are fasting X5.6 mmol l -1 , 1-h postprandial X10.3 mmol l -1 , 2-h postprandial X8.6 mmol l -1 , 3-h postprandial X6.7 mmol l -1 ). The exclusion criteria were (1) prepregnancy diabetes mellitus, hypertension, polycystic ovarian syndrome, collagen vascular diseases, intrauterine infection, inflammatory conditions or other life-threatening conditions; (2) current use of corticosteroids or diuretic; (3) multiple pregnancy; (4) maternal age <20 or >40 years; (5) infants with gestational age <37.0 or X42.0 weeks and (6) congenital malformations. After being diagnosed GDM, all subjects first received medical nutrition therapy and exercise intervention. Blood glucose is the key parameter to evaluate maternal glucose control. According to the standards of glucose control goals stated by Chinese Diabetes Society in 2007, maternal blood glucose levels should be monitored up to six times a day: upon awakening (fasting), before lunch and dinner and 2-h after the first bite of each meal. The goals are (1) the morning fasting glucose level is <100 mg dl -1 ; (2) the glucose levels before lunch and dinner are <100 mg dl -1 and (3) the 2-h postprandial glucose level is p120 mg dl -1 . Study demonstrates that during labor, the placenta may contribute to cord blood Ang II concentration. 15 In our study, we finally enrolled 30 pregnant women with GDM (GDM group) and 30 pregnant women with normal glucose tolerance (NGT group) who underwent elective cesarean deliveries. The indications for cesarean deliveries are shown in Table 1 . All subjects gave informed consent with the indications for cesarean deliveries and the potential risk of complications of cesarean delivery. Most of the subjects with GDM achieved tight glucose control after 2 weeks of diet and exercise intervention except three subjects, who also achieved tight glucose control with insulin therapy till cesarean delivery.
Anthropometric measurements
Maternal characteristics including age, height, pre-pregnancy weight, late pregnancy weight and blood pressure were evaluated before delivery. Body mass index (BMI), an indicator of maternal adiposity, was calculated as body weight (kg)/(height (m)) 2 . Neonatal data including gestational age, weight, length and sex were evaluated at delivery. Birth weight was determined to the nearest 10 g using a standardized electronic scale. Length was measured to the nearest 0.1 cm using a standardized length board. Ponderal index (PI), an anthropometric index of fetal adiposity, was calculated as body weight (g)/(height (cm)) 3 Â 100. All these measurements were performed routinely by an experienced nurse.
Cord blood assays
Venous cord blood samples were obtained by syringe from the double-clamped cord before delivery of the placenta. Serum or plasma was separated by centrifugation and stored frozen at À80 1C. Serum Ang II was measured using enzyme-linked immunosorbent assay kit (Enzo Life Sciences, GmbH, Lorrach, Germany). Plasma glucose was measured immediately after sampling by the glucose oxidase method with an automatic chemistry analyzer. Serum insulin was measured using an insulin RIA (radioimmunoassay) kit (Beijing Atom High Tech, Beijing, China) with a fully automated r RIA-immunity analyzer (Xi'an Nuclear Instrument Factory, Xi'an, China). Fetal insulin sensitivity was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR): fasting glucose (mmol l -1 ) Â fasting insulin (mU l -1 )/22.5. 16 Increased HOMA-IR indicates decreased insulin sensitivity.
Statistical analysis
The values are presented as mean±s.d., median (interquartile range) or proportions. Differences between groups were examined with w 2 test or Student's t-test or Mann-Whitney U-test and 
Results

Anthropometric parameters
The anthropometric variables of mothers and offspring are presented in Table 2 . Pre-pregnancy BMI was higher in the GDM group compared with the NGT group. PI was higher in the GDM group compared with the NGT group, and the difference was more significant after adjustment for gestational age and fetal sex between the two groups. There were no significant differences in maternal age, late pregnancy BMI, blood pressure, fetal sex, gestational age, birth weight and length between the two groups.
Cord blood parameters
Cord blood concentrations of Ang II and insulin were significantly higher in the GDM group compared with the NGT group. These differences remained significant after adjustment for maternal age, pre-pregnancy BMI, gestational age, fetal sex and PI (Table 3 ; Figure 1 ). Cord blood glucose concentration and HOMA-IR did not differ significantly between the two groups. But HOMA-IR was significantly higher in the GDM group compared with the NGT group after adjustment for maternal age, pre-pregnancy BMI, gestational age, fetal sex and PI (Table 3) .
Relationship between fetal insulin sensitivity and adiposity Cord blood insulin concentration was positively associated with birth weight (r ¼ 0.36, P ¼ 0.004) and PI (r ¼ 0.42, P ¼ 0.001). HOMA-IR was positively associated with PI (r ¼ 0.29, P ¼ 0.028), whereas was not associated with birth weight (r ¼ 0.23, P ¼ 0.076). Cord blood insulin concentration and HOMA-IR were not associated with maternal pre-pregnancy BMI, late pregnancy BMI, blood pressure, fetal sex and gestational age (data not shown).
Relationship between cord blood Ang II and fetal insulin sensitivity and adiposity Cord blood Ang II concentration was positively associated with HOMA-IR in the GDM group, whereas was negatively associated with cord blood insulin concentration in the NGT group. These relationships remained significant after adjustment for maternal age, pre-pregnancy BMI, gestational age, fetal sex and PI (Table 4) . Cord blood Ang II concentration was not associated with cord blood glucose concentration, maternal pre-pregnancy BMI, late pregnancy BMI, systolic blood pressure, diastolic blood pressure, birth weight and PI (data not shown).
Discussion
In the present study, we found that cord blood glucose concentration did not differ significantly between the GDM and NGT groups. But cord blood insulin concentration increased in the offspring of mothers with GDM. This indicates that the offspring of mothers with GDM enhance insulin secretory response to maintain glucose homeostasis. Till now, there is limited information on estimates of insulin sensitivity in the offspring of mothers with GDM. Euglycemic glucose clamp can not be applied to newborn practically at birth though it is considered to be the gold standard method for directly measuring insulin sensitivity in vivo. Consistent with other studies, 16, 17 fetal insulin sensitivity was assessed by calculating HOMA-IR index at birth in our study. Excess adipose tissue combined with decreased insulin sensitivity is a central pathogenic mechanism in adults with obesity and T2DM. However, whether it is also a central feature of the metabolic dysregulation during in utero development for the offspring of mothers with GDM remains to be determined. Our study showed increased fetal adiposity accompanied with decreased insulin sensitivity in the offspring of mothers with GDM. And cord blood insulin concentration was positively associated with fetal adiposity, whereas fetal insulin sensitivity was negatively associated with fetal adiposity in all the offspring. Fetal insulin is regarded as an anabolic factor for the intrauterine fetal development. Catalano et al 17 reported that fetal hyperinsulinemia is associated with increased fat mass in utero in the offspring of obese mothers. Pedersen 18 reported that fetal hyperinsulinemia results in fetal overgrowth, particularly in women with diabetes. Westgate et al Cord Ang II concentration and fetal insulin sensitivity F Zhang et al reported that fetal hyperinsulinemia is a common outcome of pregnancy in women with T2DM and GDM in New Zealand.
19
In agreement with these studies, our findings highlight the association between fetal hyperinsulinemia/decreased insulin sensitivity and increased fetal adiposity in the offspring of mothers with GDM. The present study revealed that cord blood Ang II concentration significantly increased and negatively associated with decreased insulin sensitivity in the offspring of mothers with GDM. Circulating Ang II may be a key marker of the RAS, which is involved in decreased insulin sensitivity in obesity. Ang II infusion can decrease insulin sensitivity in diabetic and non-diabetic rats. 20 In obese patients with T2DM, blood Ang II concentration is negatively associated with lipoprotein lipase mass during weight loss, and lipoprotein lipase mass in preheparin serum has been reported to reflect insulin sensitivity. 12, 21 Ang II decreases insulin sensitivity through the following mechanisms: (1) decreases islet and skeletal muscle blood flow, (2) increases oxidative stress and islet fibrosis and (3) interacts with insulin signaling. 22, 23 Furthermore, the increased concentrations of Ang II and insulin and decreased insulin sensitivity can cooperate with the impaired endothelial and vascular functions. Plasma concentrations of Ang II and insulin increase in insulin-treated diabetic rats, which can lead to vasoconstriction. 24 Bian et al 25 reported that exposure of human umbilical venous endothelium cells to Ang II induces endothelial apoptosis. In addition, RAS inhibitors, including ACEIs or ARBs, can increase insulin sensitivity by downregulating blood Ang II concentration. 9 RAS inhibitors can also decrease the incidence of new-onset diabetes in patients with hypertension. 7 On the other hand, decreased insulin sensitivity can also enhance insulin secretion and lead to hyperinsulinemia, which can induce the activation of the RAS. Hyperinsulinemia promotes Ang II activity by upregulating Ang II receptor expression and enhancing Ang II secretion. 26, 27 Pioglitazone, an insulin-sensitizing thiazolidinedione agent, can decrease plasma Ang II concentration in patients with T2DM. 28 In conclusion, increased Ang II Cord Ang II concentration and fetal insulin sensitivity F Zhang et al concentration is associated with decreased insulin sensitivity in adults with obesity or/and T2DM. And from our study, this has also been demonstrated in the fetuses of mothers with GDM at birth. Despite its effect of decreasing insulin sensitivity, Ang II can also promote adipocyte growth and differentiation. 9 On the other hand, enlarged adipocytes may consequently produce more Ang II, which may influence glucose and lipid metabolism in metabolic organs including adipocytes. Studies demonstrate that adipogenic differentiation is associated with a marked increase in Ang II expression in human preadipocytes. 29, 30 Saiki et al 12 reported that they measure plasma Ang II concentration by RIA, and verify that it decreases during weight loss in obese subjects with T2DM. In our study, cord blood Ang II concentration was not associated with fetal adiposity in the offspring of mothers with GDM. Cord blood Ang II concentration was measured by enzyme immunoassay in our study; and it might be one of the reasons why we could not verify the association.
In our study, 43 of 60 pregnant women underwent elective cesarean deliveries because of maternal/family request, which reflects a high rate of cesarean delivery without clinical indication. Reasons for this are multifaceted. On one hand, owing to the one child policy in China, wealthy and well-educated women may prefer birth by cesarean delivery to vaginal delivery because they fear the consequences of vaginal delivery. All these women gave informed consent with the indication for cesarean delivery categorized as 'woman's request' or 'due to social factors' and the potential risks of complications of cesarean delivery. On the other hand, the rise in demand for cesarean delivery is mostly stimulated by hospitals and health-care providers and this costly procedure has become their vital source of revenue. This has definitely led to the rise of total expenditure on cesarean delivery and a serious resource drain in China. This problem warrants attention from pregnant women, the health-care providers and the Chinese government.
Conclusion
This is the first study to determine cord blood Ang II concentration and to assess its relationship to fetal insulin sensitivity and adiposity in the offspring of mothers with GDM at birth. Our findings demonstrate that fetal decreased insulin sensitivity was associated with increased cord blood Ang II concentration and fetal adiposity in the offspring of mothers with GDM, whereas cord blood Ang II concentration was not associated with fetal adiposity. Further investigation is warranted to examine cord blood Ang II concentration by RIA and estimate the association between cord blood Ang II concentration and fetal adiposity. Our study only investigated the metabolic status in the offspring of mothers with GDM at birth, so it cannot demonstrate the vicious cycle of 'diabetes begetting diabetes' in mothers with GDM and their offspring. Follow-up study examining the postpartum metabolic status of mothers with GDM and their offspring enrolled in the present study has already been performed.
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